CBIO
Crescent Biopharma
CBIO
CBIO
63 hedge funds and large institutions have $477M invested in Crescent Biopharma in 2026 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 8 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
9% more funds holding
Funds holding: 58 → 63 (+5)
79.42% less ownership
Funds ownership: 173.59% → 94.17% (-79%)
Holders
63
Holding in Top 10
4
Calls
–
Puts
–
Top Buyers
| 1 | +$16.1M | |
| 2 | +$3.3M | |
| 3 | +$3M | |
| 4 |
Goldman Sachs
New York
|
+$2.33M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$2.05M |
Top Sellers
| 1 | -$6.38M | |
| 2 | -$3.59M | |
| 3 | -$3.13M | |
| 4 |
PA
Perceptive Advisors
New York
|
-$2.83M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.63M |
